Skip to content
RNAWiki
Checking…
All public datasets

Public dataset

Recorded enzyme and transporter findings by polarity

Inspect every admitted source sentence for an exact medicine, enzyme or transporter, and recorded role, with assertions, denials, and unresolved polarity counted separately.

What this does not mean: This is not a drug interaction checker. A denial applies only to the named medicine, role, counterparty, conditions, and source sentence; it is not proof of no interaction and is not dosing or treatment advice.
Public rows
8,404
Generated
Schema version
1.3.0

Coverage

What this run contains

Medicine–counterparty–role groups
8,404
Source sentence records
20,358
Asserted sentences
4,700
Denied sentences
7,494
Polarity not recorded
8,164
Medicines represented
755
Counterparties represented
36
Corpus records considered
9,855
All corpus records were checked; a record without a documented counterparty cannot produce a row in this projection.
inducer groups
617
inhibitor groups
3,131
not_recorded groups
3,074
substrate groups
1,582

Method

How the rows were made

  1. A deterministic parser reads recorded FDA-label excerpts for named enzymes and transporters.
  2. A mention is admitted only when the stored excerpt contains the recorded counterparty, allowing letter-case differences only.
  3. Every admitted mention is grouped by exact medicine slug, recorded counterparty spelling, and exact role. A missing role remains NOT_RECORDED rather than being assigned to another group.
  4. Each sentence carries the exact source version and effective date when recorded; the API serializes null and the page says not recorded when either is absent.
  5. The API paginates groups. Within each returned group, sentences is the complete untruncated list used by the three polarity counts.

Limits

Read these before using a row

  • A recorded role is a mechanistic statement copied from a descriptive label section. It is not a clinical interaction, and nothing in this dataset describes what happens when a person is exposed to two medicines at once.
  • This dataset holds no relation between one medicine and another. Counts are per counterparty; the medicines naming a counterparty are listed with their sentences and are never paired, ranked against each other or compared.
  • ICH M12 states that no potency classification system exists for transporters or for non-CYP enzymes, so no strong, moderate or weak vocabulary is applied to any counterparty here. The tallies count records, not strength.
  • A counterparty with a high count is one that labels document often. Documentation frequency is not importance: US labelling asks for some enzymes to be characterised far more routinely than others, and that requirement is part of what these counts measure.
  • 40.1% of admitted mentions carry no role. The sentence named more than one role and the parser left the question open rather than attaching a guess, so a role tally is a count of sentences that settled the question, not of medicines for which it is settled.
  • Recorded spellings are counted separately and never merged. P-GP, PGP and P-GLYCOPROTEIN are three entries in this dataset because they are three strings in the corpus; whether they name one thing is a question for a person, and prefix relationships are reported as questions rather than resolved.
  • 9088 of 9855 records name no enzyme or transporter at all. That is an absence of recorded text in the sources fetched for those records. It is neither reassurance nor alarm about the medicines concerned.
  • 20358 of 20358 admitted mentions come from records the deterministic label parser produced, where no person chose the value or wrote its measurement context. The sentence is stored with each one so a reader can check it.
  • The uniform reference for concentration allocates the same 20358 mentions over the same 36 counterparties by chance. Labels are not written that way, so the reference shows only that the observed spread is not a consequence of how many mentions there are.
  • The public rows enumerate documentation about one medicine and one named counterparty. They never create medicine-to-medicine pairs and cannot answer whether two medicines interact.
  • A NOT_RECORDED role or polarity remains unresolved. It is never folded into an assertion or a denial.
  • Each returned group includes every admitted source sentence for checking, but the full source document remains authoritative.

Provenance

Source examples

Abacavir · CYP3A4 inhibitor

2 asserted · 2 denied · 0 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
In vitro experiments reveal that abacavir does not inhibit human CYP3A4, CYP2D6, or CYP2C9 activity at clinically relevant concentrations.

Abacavir · BCRP substrate

0 asserted · 4 denied · 0 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
Based on in vitro study results, abacavir at therapeutic drug exposures is not expected to affect the pharmacokinetics of drugs that are substrates of the following transporters: organic anion transporter polypeptide (OATP)1B1/3, breast cancer resistance protein (BCRP) or P-glycoprotein (P-gp), organic cation transporter (OCT)1, OCT2, or multidrug and toxic extrusion protein (MATE)1 and MATE2-K.

Abacavir · CYP2C9 not_recorded

0 asserted · 0 denied · 2 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
Abacavir did not inhibit or induce other CYP enzymes (such as CYP2C9, or CYP2D6).

Artifact used for this view: data/agents/current/enzyme-and-transporter-documentation.json. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.

Schema

Fields in the public projection

FieldTypeMeaning
medicineSlugstringStable RNAWiki medicine route key.
medicineNamestringRecorded medicine name; not normalized for display style.
counterpartystringThe exact recorded counterparty spelling.
rolestringSUBSTRATE, INHIBITOR, INDUCER, or NOT_RECORDED when the sentence did not settle one role.
assertedCountnumberSentence records whose polarity is ASSERTED.
deniedCountnumberSentence records whose polarity is NEGATED.
polarityNotRecordedCountnumberSentence records for which the parser did not settle assertion or denial.
sentencessentence[]Every admitted sentence for this group, with polarity, section, source identity, source version/effective date or explicit absence, retrieval date, and exact excerpt. The list is not truncated.

Reader

Search and filter the rows

Case-insensitive text search over the public fields named for this dataset.

Exact recorded role.

Exact recorded counterparty spelling.

Clear

Showing 181–190 of 8,404 matching rows. Filters and search terms remain attached when you move between pages or open the API view.

  1. Projected row 181

    Medicine slug
    alectinib
    Medicine name
    Alectinib
    Enzyme or transporter
    P-GLYCOPROTEIN
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    2
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:42c49deb-713b-427a-9670-08af08adcffb (opens source in a new tab)

      Alectinib label

      Version not recorded · Effective date not recorded

      In vitro studies suggest that alectinib is not a substrate of P-glycoprotein (P-gp), but M4 is a substrate of P-gp.
    2. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:42c49deb-713b-427a-9670-08af08adcffb (opens source in a new tab)

      Alectinib label

      Version not recorded · Effective date not recorded

      In vitro studies suggest that alectinib is not a substrate of P-glycoprotein (P-gp), but M4 is a substrate of P-gp.

  2. Projected row 182

    Medicine slug
    alectinib
    Medicine name
    Alectinib
    Enzyme or transporter
    P-GP
    Role
    INHIBITOR
    Asserted sentences
    2
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:42c49deb-713b-427a-9670-08af08adcffb (opens source in a new tab)

      Alectinib label

      Version not recorded · Effective date not recorded

      In vitro studies suggest that alectinib and M4 inhibit P-gp and BCRP.
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:42c49deb-713b-427a-9670-08af08adcffb (opens source in a new tab)

      Alectinib label

      Version not recorded · Effective date not recorded

      In vitro studies suggest that alectinib and M4 inhibit P-gp and BCRP.

  3. Projected row 183

    Medicine slug
    alectinib
    Medicine name
    Alectinib
    Enzyme or transporter
    P-GP
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    2
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:42c49deb-713b-427a-9670-08af08adcffb (opens source in a new tab)

      Alectinib label

      Version not recorded · Effective date not recorded

      In vitro studies suggest that alectinib is not a substrate of P-glycoprotein (P-gp), but M4 is a substrate of P-gp.
    2. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:42c49deb-713b-427a-9670-08af08adcffb (opens source in a new tab)

      Alectinib label

      Version not recorded · Effective date not recorded

      In vitro studies suggest that alectinib is not a substrate of P-glycoprotein (P-gp), but M4 is a substrate of P-gp.

  4. Projected row 184

    Medicine slug
    alfuzosin
    Medicine name
    Alfuzosin
    Enzyme or transporter
    CYP1A2
    Role
    INHIBITOR
    Asserted sentences
    0
    Denied sentences
    2
    Polarity not recorded
    0
    Complete sentence records
    1. NEGATEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:43675e9d-a361-4109-9ae1-54d80580fbbd (opens source in a new tab)

      Alfuzosin label

      Version not recorded · Effective date not recorded

      In human liver microsomes, at concentrations that are achieved at the therapeutic dose, alfuzosin did not inhibit CYP1A2, 2A6, 2C9, 2C19, 2D6 or 3A4 isoenzymes.
    2. NEGATEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:43675e9d-a361-4109-9ae1-54d80580fbbd (opens source in a new tab)

      Alfuzosin label

      Version not recorded · Effective date not recorded

      In human liver microsomes, at concentrations that are achieved at the therapeutic dose, alfuzosin did not inhibit CYP1A2, 2A6, 2C9, 2C19, 2D6 or 3A4 isoenzymes.

  5. Projected row 185

    Medicine slug
    alfuzosin
    Medicine name
    Alfuzosin
    Enzyme or transporter
    CYP3A4
    Role
    INHIBITOR
    Asserted sentences
    6
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:43675e9d-a361-4109-9ae1-54d80580fbbd (opens source in a new tab)

      Alfuzosin label

      Version not recorded · Effective date not recorded

      Potent CYP3A4 Inhibitors Repeated oral administration of 400 mg/day of ketoconazole, a potent inhibitor of CYP3A4, increased alfuzosin C max by 2.3-fold and AUC last by 3.2-fold, following a single 10 mg dose of alfuzosin.
    2. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:43675e9d-a361-4109-9ae1-54d80580fbbd (opens source in a new tab)

      Alfuzosin label

      Version not recorded · Effective date not recorded

      Therefore, alfuzosin hydrochloride extended-release tablets are contraindicated for co-administration with potent inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, or ritonavir) because of increased alfuzosin exposure [see Contraindications (4) , Warnings and Precautions (5.4) and Drug Interactions (7.1) ] .
    3. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:43675e9d-a361-4109-9ae1-54d80580fbbd (opens source in a new tab)

      Alfuzosin label

      Version not recorded · Effective date not recorded

      Moderate CYP3A4 Inhibitors Diltiazem: Repeated co-administration of 240 mg/day of diltiazem, a moderately-potent inhibitor of CYP3A4, with 7.5 mg/day (2.5 mg three times daily) alfuzosin (equivalent to the exposure with alfuzosin hydrochloride extended-release tablets) increased the C max and AUC 0-24 of alfuzosin 1.5- and 1.3-fold, respectively.
    4. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:43675e9d-a361-4109-9ae1-54d80580fbbd (opens source in a new tab)

      Alfuzosin label

      Version not recorded · Effective date not recorded

      Potent CYP3A4 Inhibitors Repeated oral administration of 400 mg/day of ketoconazole, a potent inhibitor of CYP3A4, increased alfuzosin C max by 2.3-fold and AUC last by 3.2-fold, following a single 10 mg dose of alfuzosin.
    5. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:43675e9d-a361-4109-9ae1-54d80580fbbd (opens source in a new tab)

      Alfuzosin label

      Version not recorded · Effective date not recorded

      Therefore, alfuzosin hydrochloride extended-release tablets are contraindicated for co-administration with potent inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, or ritonavir) because of increased alfuzosin exposure [see Contraindications (4) , Warnings and Precautions (5.4) and Drug Interactions (7.1) ] .
    6. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:43675e9d-a361-4109-9ae1-54d80580fbbd (opens source in a new tab)

      Alfuzosin label

      Version not recorded · Effective date not recorded

      Moderate CYP3A4 Inhibitors Diltiazem: Repeated co-administration of 240 mg/day of diltiazem, a moderately-potent inhibitor of CYP3A4, with 7.5 mg/day (2.5 mg three times daily) alfuzosin (equivalent to the exposure with alfuzosin hydrochloride extended-release tablets) increased the C max and AUC 0-24 of alfuzosin 1.5- and 1.3-fold, respectively.

  6. Projected row 186

    Medicine slug
    alfuzosin
    Medicine name
    Alfuzosin
    Enzyme or transporter
    CYP3A4
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    4
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:43675e9d-a361-4109-9ae1-54d80580fbbd (opens source in a new tab)

      Alfuzosin label

      Version not recorded · Effective date not recorded

      CYP3A4 is the principal hepatic enzyme isoform involved in its metabolism.
    2. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:43675e9d-a361-4109-9ae1-54d80580fbbd (opens source in a new tab)

      Alfuzosin label

      Version not recorded · Effective date not recorded

      Drug-Drug Interactions Metabolic Interactions CYP3A4 is the principal hepatic enzyme isoform involved in the metabolism of alfuzosin.
    3. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:43675e9d-a361-4109-9ae1-54d80580fbbd (opens source in a new tab)

      Alfuzosin label

      Version not recorded · Effective date not recorded

      CYP3A4 is the principal hepatic enzyme isoform involved in its metabolism.
    4. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:43675e9d-a361-4109-9ae1-54d80580fbbd (opens source in a new tab)

      Alfuzosin label

      Version not recorded · Effective date not recorded

      Drug-Drug Interactions Metabolic Interactions CYP3A4 is the principal hepatic enzyme isoform involved in the metabolism of alfuzosin.

  7. Projected row 187

    Medicine slug
    alirocumab
    Medicine name
    Alirocumab
    Enzyme or transporter
    CYP2C9
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    2
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:446f6b5c-0dd4-44ff-9bc2-c2b41f2806b4 (opens source in a new tab)

      Alirocumab label

      Version not recorded · Effective date not recorded

      In clinical studies where alirocumab was administered in combination with atorvastatin or rosuvastatin, no relevant changes in statin concentrations were observed in the presence of repeated administration of alirocumab, indicating that cytochrome P450 enzymes (mainly CYP3A4 and CYP2C9) and transporter proteins such as P-gp and OATP were not affected by alirocumab.
    2. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:446f6b5c-0dd4-44ff-9bc2-c2b41f2806b4 (opens source in a new tab)

      Alirocumab label

      Version not recorded · Effective date not recorded

      In clinical studies where alirocumab was administered in combination with atorvastatin or rosuvastatin, no relevant changes in statin concentrations were observed in the presence of repeated administration of alirocumab, indicating that cytochrome P450 enzymes (mainly CYP3A4 and CYP2C9) and transporter proteins such as P-gp and OATP were not affected by alirocumab.

  8. Projected row 188

    Medicine slug
    alirocumab
    Medicine name
    Alirocumab
    Enzyme or transporter
    CYP3A4
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    2
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:446f6b5c-0dd4-44ff-9bc2-c2b41f2806b4 (opens source in a new tab)

      Alirocumab label

      Version not recorded · Effective date not recorded

      In clinical studies where alirocumab was administered in combination with atorvastatin or rosuvastatin, no relevant changes in statin concentrations were observed in the presence of repeated administration of alirocumab, indicating that cytochrome P450 enzymes (mainly CYP3A4 and CYP2C9) and transporter proteins such as P-gp and OATP were not affected by alirocumab.
    2. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:446f6b5c-0dd4-44ff-9bc2-c2b41f2806b4 (opens source in a new tab)

      Alirocumab label

      Version not recorded · Effective date not recorded

      In clinical studies where alirocumab was administered in combination with atorvastatin or rosuvastatin, no relevant changes in statin concentrations were observed in the presence of repeated administration of alirocumab, indicating that cytochrome P450 enzymes (mainly CYP3A4 and CYP2C9) and transporter proteins such as P-gp and OATP were not affected by alirocumab.

  9. Projected row 189

    Medicine slug
    alirocumab
    Medicine name
    Alirocumab
    Enzyme or transporter
    OATP
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    2
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:446f6b5c-0dd4-44ff-9bc2-c2b41f2806b4 (opens source in a new tab)

      Alirocumab label

      Version not recorded · Effective date not recorded

      In clinical studies where alirocumab was administered in combination with atorvastatin or rosuvastatin, no relevant changes in statin concentrations were observed in the presence of repeated administration of alirocumab, indicating that cytochrome P450 enzymes (mainly CYP3A4 and CYP2C9) and transporter proteins such as P-gp and OATP were not affected by alirocumab.
    2. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:446f6b5c-0dd4-44ff-9bc2-c2b41f2806b4 (opens source in a new tab)

      Alirocumab label

      Version not recorded · Effective date not recorded

      In clinical studies where alirocumab was administered in combination with atorvastatin or rosuvastatin, no relevant changes in statin concentrations were observed in the presence of repeated administration of alirocumab, indicating that cytochrome P450 enzymes (mainly CYP3A4 and CYP2C9) and transporter proteins such as P-gp and OATP were not affected by alirocumab.

  10. Projected row 190

    Medicine slug
    alirocumab
    Medicine name
    Alirocumab
    Enzyme or transporter
    P-GP
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    2
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:446f6b5c-0dd4-44ff-9bc2-c2b41f2806b4 (opens source in a new tab)

      Alirocumab label

      Version not recorded · Effective date not recorded

      In clinical studies where alirocumab was administered in combination with atorvastatin or rosuvastatin, no relevant changes in statin concentrations were observed in the presence of repeated administration of alirocumab, indicating that cytochrome P450 enzymes (mainly CYP3A4 and CYP2C9) and transporter proteins such as P-gp and OATP were not affected by alirocumab.
    2. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:446f6b5c-0dd4-44ff-9bc2-c2b41f2806b4 (opens source in a new tab)

      Alirocumab label

      Version not recorded · Effective date not recorded

      In clinical studies where alirocumab was administered in combination with atorvastatin or rosuvastatin, no relevant changes in statin concentrations were observed in the presence of repeated administration of alirocumab, indicating that cytochrome P450 enzymes (mainly CYP3A4 and CYP2C9) and transporter proteins such as P-gp and OATP were not affected by alirocumab.

Access

Query or download the projection

View this filtered page as JSONDownload up to 200 filtered CSV rows
GET /api/datasets/enzyme-transporter-negatives?limit=10&offset=180

Allowed query parameters

q
Case-insensitive text search over the public fields named for this dataset.
role
Exact recorded role.Values: INDUCER, INHIBITOR, NOT_RECORDED, SUBSTRATE
counterparty
Exact recorded counterparty spelling.
limit / offset
Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.

Reuse and corrections

Keep the boundary attached

CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.

Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.

Read the correction policy